Sai Life Sciences Ltd. IPO – A Detailed Analysis - English

India’s pharmaceutical research and manufacturing services sector is on a strong growth trajectory, projected to grow at a CAGR of 9-10% and touch ~₹4.5 lakh crore by 2028. This growth is driven by increasing global demand for generic medicines, outsourcing of R&D and manufacturing. Sai Life Sciences, a player in drug discovery, development, and manufacturing, is riding this wave with its IPO. But does it hold the right potential for listing gains or long-term growth? Let’s dive into its business, financials, and valuations to find out.